L&C BIO Co., Ltd Logo

L&C BIO Co., Ltd

Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.

290650 | KO

Overview

Corporate Details

ISIN(s):
KR7290650001
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 474, 605호, 606호, 607호 (선텍시티), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

L&C BIO Co., Ltd. is a biotechnology company specializing in tissue regeneration medicine. The company develops and manufactures human tissue grafts, allograft-based medical devices, and cosmetics. It is a leader in the South Korean skin graft market and operates one of Asia's largest skin and soft tissue banks, utilizing patented processing technologies. Committed to continuous research and development, L&C BIO aims to improve global health and quality of life by becoming a leading global bio-health company.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-08-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 35.7 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.7 MB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 73.0 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 79.5 KB
2025-06-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 143.2 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-23 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.8 KB
2025-06-16 00:00
Capital/Financing Update
[기재정정]교환사채권발행결정(종속회사의주요경영사항)
Korean 36.9 KB
2025-06-12 00:00
Capital/Financing Update
교환사채권발행결정(종속회사의주요경영사항)
Korean 32.6 KB
2025-06-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 79.9 KB
2025-06-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 75.3 KB
2025-05-27 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 12.7 KB
2025-05-27 00:00
Share Issue/Capital Change
전환청구권행사
Korean 10.0 KB
2025-05-26 00:00
Share Issue/Capital Change
주요사항보고서(제3자의전환사채매수선택권행사)
Korean 16.3 KB

Automate Your Workflow. Get a real-time feed of all L&C BIO Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for L&C BIO Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for L&C BIO Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
MAIA Biotechnology, Inc. Logo
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America
MAIA
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.